• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.24% Nasdaq Down0.19%

    Alnylam Pharmaceuticals, Inc. (ALNY)

    -NasdaqGS
    127.56 Down 3.06(2.34%) 2:42PM EDT - Nasdaq Real Time Price
    Add to Portfolio
    Income StatementGet Income Statement for:
    View: Annual Data | Quarterly DataAll numbers in thousands
    Period EndingDec 31, 2014Dec 31, 2013Dec 31, 2012
    Total Revenue 50,561   47,167   66,725  
    Cost of Revenue -   -   -  
    Gross Profit 50,561   47,167   66,725  
    Operating Expenses
    Research Development190,249  112,957  86,569  
    Selling General and Administrative44,526  27,152  44,612  
    Non Recurring220,766   -  65,000  
    Others -   -   -  
    Total Operating Expenses -   -   -  
    Operating Income or Loss (404,980) (92,942) (129,456)
    Income from Continuing Operations
    Total Other Income/Expenses Net4,376  1,022  17,392  
    Earnings Before Interest And Taxes(400,604)(91,920)(116,586)
    Interest Expense -   -   -  
    Income Before Tax(400,604)(91,920)(116,586)
    Income Tax Expense(40,209)(2,695)(10,572)
    Minority Interest -   -   -  
    Net Income From Continuing Ops(360,395)(89,225)(110,536)
    Non-recurring Events
    Discontinued Operations -   -   -  
    Extraordinary Items -   -   -  
    Effect Of Accounting Changes -   -   -  
    Other Items -   -   -  
    Net Income (360,395) (89,225) (106,014)
    Preferred Stock And Other Adjustments -   -   -  
    Net Income Applicable To Common Shares (360,395) (89,225) (106,014)

    Sign Up for a Free Trial to EDGAR Online Premium!
    Get the critical business and financial information you need for more than 15,000 U.S. public companies.
    Sign Up Now - Learn More

    Currency in USD.